Search results
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 2 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Pensionfund Sabic Sells 3,100 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 2 days agoPensionfund Sabic lowered its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 15.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 2 days agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis& ...
American Trust Takes Position in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 6 days agoAmerican Trust acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and ...
AbbVie (NYSE:ABBV) Shares Up 0%
ETF DAILY NEWS· 7 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0% during mid-day trading on Thursday . The company traded as high as $166.45 and last traded at $166.15. ABBV has been the topic ...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks· 21 hours agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks· 3 days agoSkyrizi’s approval for the UC indication was based on data from two phase III studies, a 12-week induction study, INSPIRE1 and a 52-week maintenance study, COMMAND2. Skyrizi is already approved ...
AbbVie Inc. (NYSE:ABBV) Shares Sold by Garde Capital Inc.
ETF DAILY NEWS· 7 days agoGarde Capital Inc. lowered its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 60.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm ...
Amgen (NASDAQ:AMGN) Price Target Raised to $332.00 at Royal Bank of Canada
ETF DAILY NEWS· 7 days agoAmgen (NASDAQ:AMGN – Free Report) had its target price hoisted by Royal Bank of Canada from $328.00 to $332.00 in a research report sent to investors on Friday, Benzinga reports. Several other ...
175 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Livelsberger Financial Advisory
ETF DAILY NEWS· 4 days agoLivelsberger Financial Advisory purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The ...